NCT07541079
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07541079
Title A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Acronym novERA Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.